Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)

The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Renz, Bernhard W., D’Haese, Jan G., Werner, Jens, Westphalen, C. Benedikt, Ilmer, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635789/
https://www.ncbi.nlm.nih.gov/pubmed/29099030
http://dx.doi.org/10.3390/medsci5020014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635789/
https://www.ncbi.nlm.nih.gov/pubmed/29099030
http://dx.doi.org/10.3390/medsci5020014

Ejemplares similares